Report Overview

Indian Diabetic Retinopathy Drugs market size stood at USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period 2019-2028.

Diabetic Retinopathy is rapidly gaining the status of a potential epidemic in India with around 65 million people currently being affected by it.Diabetic Retinopathy is rapidly gaining the status of a potential epidemic in India with around 65 million people currently being affected by. Diabetic retinopathy (DR) refers to the damage caused to the blood vessels in the retina by diabetes mellitus. This ailment is of two kinds, namely non-proliferative DR and proliferative or advanced DR. It is caused by fluctuations in the blood glucose levels resulting in an abnormal growth in the light-sensitive tissues present in the eye. The symptoms of DR include the visibility of dark spots or floating strings in the vision field, blurred or fluctuating vision, impaired color vision or loss of vision. It can be diagnosed through tests, such as fluorescein angiography and optical coherence tomography, and the treatment involves the use of intraocular steroid injection, laser treatment and vitrectomy.



Market Drivers

The increasing prevalence of diabetes, along with the growing geriatric population in India, represent as the key factors driving the growth of the market. Furthermore, the rising incidence of blindness caused by DR is also providing a boost to the market growth. There is an increasing awareness among the masses regarding the available treatment alternatives and the benefits of early detection of DR. This has resulted in the widespread adoption of technologically advanced procedures and equipment, such as the improved ophthalmic diagnostic and surgical instruments. These procedures and equipment enable early detection and efficient treatment of the ailment with higher precision and minimal discomfort to the patient. Other factors, including the increasing healthcare expenditures, the implementation of favorable government policies to make advanced healthcare services available to the masses and extensive research and development (R&D) activities, are projected to drive the market further.